The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy
Open accessAbstract
Interleukin-7 (IL-7) is a non-hematopoietic cell-derived cytokine with a central role in the adaptive immune system. It promotes lymphocyte development in the thymus and maintains survival of naive and memory T cell homeostasis in the periphery. Moreover, it is important for the organogenesis of lymph nodes (LN) and for the maintenance of activated T cells recruited into the secondary lymphoid organs (SLOs). The immune capacity of cancer patients is suppressed that is characterized by lower T cell counts, less effector immune cells infiltration, higher levels of exhausted effector cells and higher levels of immunosuppressive cytokines, such as transforming growth factor β (TGF-β). Recombinant human IL-7 (rhIL-7) is an ideal solution for the immune reconstitution of lymphopenia patients by promoting peripheral T cell expansion. Furthermore, it can antagonize the immunosuppressive network. In animal models, IL-7 has been proven to prolong the survival of tumor-bearing hosts. In this review, we will focus on the mechanism of action and applications of IL-7 in cancer immunotherapy and the potential restrictions for its usage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-7R down-regulation guarantees an efficient use of the limited amount of IL-7 to naïve T cells that need it, driving their proliferation and preserving their phenotype (160).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,326
Homeostasis of Naive and Memory T Cells
Surh, C. D., & Sprent, J. (2008) · Immunity · doi:10.1016/j.immuni.2008.11.002 · Cited by 1,193
Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes.
Bajénoff, M., Egen, J., Koo, L. Y., Laugier, J., Brau, F., Glaichenhaus, N., & Germain, R. N. (2006) · Immunity · doi:10.1016/j.immuni.2006.10.011 · Cited by 1,022
Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells
Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha‐Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007) · Nature Immunology · doi:10.1038/ni1513 · Cited by 949
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
Puel, A., Ziegler, S. F., Buckley, R. H., & Leonard., W. J. (1998) · Nature Genetics · doi:10.1038/3877 · Cited by 813
Ray-Coquard, I. L., Cropet, C., Glabbeke, M. M. V., Sebban, C., Cesne, A. L., Judson, I. R., Trédan, O., Verweij, J., Biron, P., Labidi‐Galy, S. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3845 · Cited by 783
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 660
Interleukin-7 receptor expression: intelligent design
Mazzucchelli, R. I., & Durum, S. K. (2007) · Nature reviews. Immunology · doi:10.1038/nri2023 · Cited by 649
Maintaining the norm: T-cell homeostasis
Jameson, S. C. (2002) · Nature reviews. Immunology · doi:10.1038/nri853 · Cited by 597
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–122 of 122
Personalized responsiveness of human PBMCs to the action of IL-7
Kovalchuk, M. V., Рубан, Т. А., Usenko, M. O., & Кордюм, В. А. (2020) · Biopolymers and Cell · doi:10.7124/bc.000a33 · Cited by 1
Obtaining of the recombinant Rhil7-Cbd fusion protein
Usenko, M. O., Gorbatiuk, O. B., Okunev, O. V., Irodov, D. M., Kovalchuk, M. V., & Арнольдович, К. В. (2020) · Faktori eksperimental noi evolucii organizmiv · doi:10.7124/feeo.v26.1280
Strategies to Target Tumor Immunosuppression
Koutsoumpli, G., Draghiciu, O., Nijman, H. W., Oyarce, C., & Daemen, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_5
Baghbadorani, P. Z., Damavandi, A. R., Kardedeh, B., Mostafavi, S., Salehi, R., Kazemi, M., Ghasemi, R., Eskandari, N., & Fathi, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1330371/v1
Siregar, N. K., Kartono, A., & Sumaryada, T. I. (2022) · AIP conference proceedings · doi:10.1063/5.0073718
Васильевич, K. В. (2019) · Springer eBooks · doi:10.1007/978-3-030-03323-1_6
Figure S9 from Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer
Paller, C. J., Wang, L., Fu, W., Kumar, R., Durham, J. N., Azad, N. S., Laheru, D. A., Browner, I. S., Kachhap, S. K., Boyapati, K., et al. (2023) · doi:10.1158/2767-9764.22545981
Swain, A. C. (2023) · doi:10.33540/1850
CIRCULATING PROTEINS AS DIAGNOSTIC BIOMARKERS IN BREAST CANCER
Thảo, Đ. T., Thach, N. C., Tuyen, V. V., Huy, T. Q., Tuyet, N. T. A., Tuyên, N. V., & Ha, T. T. (2024) · Tạp chí Y học Quân sự · doi:10.59459/1859-1655/jmm.345
Kemmerer, C. L., Schittenhelm, J., Dubois, E., Neumann, L., Häsler, L. M., Lambert, M., Renovanz, M., Kaeser, S. A., Tabatabai, G., Ziemann, U., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16821644
Hamid, H. H., Al-joda, B. M. S., & Almamory, A. J. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.1
Caractérisation et modélisation des pathologies lymphoïdes présentant des gains du chromosome 21
Laurent, A. P. (2019) · theses.fr (ABES) · doi:10.70675/ed87382fza9bcz45fdz8589zd8c7fb99d3a9
Modifications du microenvironnement cytokinique dans les leucémies aigües myéloïdes
Guermouche, H. (2021) · theses.fr (ABES) · doi:10.70675/e0e649a1z9428z4e58z93b3z0b5d7ec2fea8
Sălăvăstru, C., Hernández‐Martín, A., Bulut, S., Fajardo, L. F., Robainas-Barcia, A., & Lajarin-Reinares, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091172
DiPiazza, A. T., Davis-Marcisak, E. F., Yu, W., Makrinos, D. L., Kuo, H.-H., Landy, J. M., McGrath, S., Chang, X., Cavallaro, M., Wu, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeh4436
Metadata
- Authors
- Gao, J., Zhao, L., Wan, Y., & Zhu, B.
- Affiliations
- Army Medical University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Wan, Yisong
- Zhu, Bo
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-05-06
- Volume
- 16
- Issue
- 5
- Pages
- 10267-10280
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4463645
- OpenAlex
- W1595607998
- Cited by
- 122
- References
- 80
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 15 · 2019: 16 · 2018: 8 · 2017: 13 · 2016: 9 · 2015: 2
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (81222031, 81071772, 81070018)
- Chongqing Science and Technology Commission
- National Key Research and Development Program of China
- National Institute of Allergy and Infectious Diseases (R01AI097392)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-7, cancer immunotherapy, T cell homeostasis, lymphocyte development, secondary lymphoid organs, T cell exhaustion, immunosuppression, TGF-beta, lymphopenia, immune reconstitution
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Signal Transduction, Interleukin-7
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
